Impact of PD-L1 Protein Expression on Renal Cell Carcinoma Histo-differentiation

Anticancer Res. 2021 Aug;41(8):3809-3813. doi: 10.21873/anticanres.15173.

Abstract

Background/aim: Renal cell carcinoma (RCC) comprises a variety of pathological entities. Many RCCs are aggressive, demanding efficient targeted and immunetherapeutic strategies. Programmed cell death ligand-1 (PD-L1) is expressed mainly in hematopoietic cells and also in epithelial cells. The aim of this study was to correlate PD-L1 protein expression in a series of RCC tissues with their histo-pathological features.

Materials and methods: One hundred (n=100) archival, formalin-fixed and paraffin-embedded RCC tissue specimens were analysed by immunohistochemistry. Conventional tumor proportion score (TPS) qualitative assay was applied for evaluating protein expression levels.

Results: Based on the TPS evaluation, 8 (8%) cases were characterized as positive, and the rest of them (n=92; 92%) as negative. A progressive increase in PD-L1 positivity was significantly associated with the differentiation grade of the examined malignancies (p=0.001).

Conclusion: Although PD-L1 over-expression is detected in low rates in RCCs, its correlation with differentiation grade should be considered as a factor for discriminating sub-groups of patients with specific histo-pathological features eligible for targeted anti-PD-L1 immunotherapy strategies.

Keywords: PD-L1; Renal; carcinoma; differentiation; immunotherapy; protein.

MeSH terms

  • B7-H1 Antigen / metabolism*
  • Biomarkers, Tumor / metabolism*
  • Carcinoma, Renal Cell / metabolism
  • Carcinoma, Renal Cell / pathology*
  • Cell Differentiation
  • Female
  • Humans
  • Kidney Neoplasms / metabolism
  • Kidney Neoplasms / pathology*
  • Male

Substances

  • B7-H1 Antigen
  • Biomarkers, Tumor
  • CD274 protein, human